ArticleCritical care explorations2025
Metabolomics for the Diagnosis of Secondary Infections in Critically Ill Patients With COVID-19.
Article in Critical care explorations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSecondary infections are a common occurrence in critically ill COVID-19 patients. These are difficult to identify, and antibiotic usage is high in this population. Identification of biomarkers for secondary infections would help to ensure antibiotics are being utilized only for patients who require them. This study sought to identify a panel of biomarkers capable of distinguishing critically ill COVID-19 patients with and without secondary infections.
designA multicenter retrospective cohort study.
settingThree critical care units in Scotland, United Kingdom. PATIENTS: One hundred five patients admitted to critical care with COVID-19, and 49 healthy volunteer controls.
interventionsNone. MEASUREMENTS AND MAIN
resultsSerial blood samples were obtained from critically ill COVID-19 patients with and without confirmed secondary infections, and a single sample was collected from healthy volunteers to provide baseline metabolic profiles. Metabolomic analysis was performed using liquid chromatography-mass spectrometry, and metabolites that were significantly different between patients with and without secondary infections were identified. Additionally, metabolites capable of distinguishing Gram-positive from Gram-negative organisms were also investigated. Forty patients developed a secondary infection during the study period. A significant increase in metabolites creatine and 2-hydroxyisovalerylcarnitine, and a significant reduction in S-methyl-L-cysteine were detected in patients with secondary infections. This metabolite panel could identify patients with secondary infections with an area under the curve (AUC) of 0.83 (95% CI, 0.68-0.97). Metabolites differentiating Gram-positive and Gram-negative infections included betaine, N(6)-methyllysine, and phosphatidylcholines (PCs; 38:6), PC(38:4), PC(40:6), and PC(36:4) with an AUC of 0.88 (95% CI, 0.68-1.0).
conclusionsMetabolomic profiling of critically ill COVID-19 shows promise for identification of novel biomarkers for secondary infections. Larger validation studies will help to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.